In this issue:
KRAS G13D mutations and outcome in cetuximab-treated mCRC
Cediranib + FOLFOX/CAPOX in mCRC
Cediranib + mFOLFOX6 vs bevacizumab + mFOLFOX6 in mCRC
Predicting 5FU toxicity in CRC
OxFU vs OxCap in advanced CRC
PIK3CA mutation in CRC: biomarker for adjuvant a
Please login below to download this issue (PDF)